A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

Keyphrases

• Alzheimer's Disease 50%
• Atrophy 50%
• Cerebrospinal Fluid Biomarkers 50%
• Clinical Markers 50%
• Clinical Trials 50%
• Disease Progression 100%
• Disease-related 50%
• Dominantly Inherited Alzheimer's Disease 100%
• Hypometabolism 50%
• Imaging Biomarkers 50%
• Metabolic Markers 50%
• Multiple Sites 50%
• Neurodegeneration 50%
• P-tau181 50%
• P-tau217 50%
• Phosphorylated tau 100%
• Phosphorylation State 100%
• Site-specific Phosphorylation 50%
• State Change 50%
• Structural Marker 50%
• Symptom Onset 50%
• Tau Amyloid 100%
• Tau Pathology 50%
• Tau Phosphorylation 50%
• Tau Protein 50%
• Tau-based Therapies 50%
• Total tau 50%

Neuroscience

• Alzheimer's Disease 100%
• Amyloid Protein 100%
• Neurodegeneration 33%
• Tau Protein 33%

Biochemistry, Genetics and Molecular Biology

• Amyloid Protein 100%
• Clinical Trial 10%
• Liquid 10%
• Tau 100%
• Tau Protein 10%